期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 14, 期 6, 页码 758-786出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0078
关键词
-
类别
资金
- Johnson Johnson
- ARIAD Pharmaceuticals, Inc.
- Bayer HealthCare
- Blueprint Medicines
- Deciphera Pharmaceuticals, LLC
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Genentech, Inc.
- Bristol-Myers Squibb Company
- Children's Oncology Group
- Astex Pharmaceuticals, Inc.
- CytRx Corporation
- Eisai Inc.
- Morphotek Inc.
- Plexxikon Inc.
- Threshold Pharmaceuticals
- TRACON Pharmaceuticals, Inc.
- AB Science
- Amgen Inc.
- BioMed Valley Discoveries, Inc.
- SARC Threshold Pharmaceuticals
- Daiichi-Sankyo Co.
- ImClone Systems Incorporated
- AROG Pharmaceuticals LLC
- ArQule, Inc.
- Immune Design
- Janssen Pharmaceutical Products, LP
- Merck Co., Inc.
- SARC
- Synta Pharmaceuticals Corp.
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for Soft Tissue Sarcoma (available at NCCN.org) provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumor, desmoid tumors, and rhabdomyosarcoma. This manuscript discusses guiding principles for the diagnosis and staging of STS and evidence for treatment modalities that include surgery, radiation, chemoradiation, chemotherapy, and targeted therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据